Andrew John Partridge Sells 1,491 Shares of GRAIL (NASDAQ:GRAL) Stock

GRAIL, Inc. (NASDAQ:GRAL) insider Andrew John Partridge sold 1,491 shares of the firm’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $61.08, for a total value of $91,070.28. Following the transaction, the insider owned 163,738 shares in the company, valued at approximately $10,001,117.04. This trade represents a 0.90% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

GRAIL Trading Down 9.9%

Shares of GRAL opened at $59.98 on Friday. GRAIL, Inc. has a 1 year low of $29.95 and a 1 year high of $118.84. The stock has a market cap of $2.57 billion, a P/E ratio of -5.78 and a beta of 3.15. The stock’s 50-day moving average price is $57.27 and its two-hundred day moving average price is $75.49.

GRAIL (NASDAQ:GRAL) last issued its earnings results on Tuesday, May 5th. The company reported ($2.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.76) by $0.47. GRAIL had a negative return on equity of 16.42% and a negative net margin of 253.22%.The firm had revenue of $40.79 million for the quarter, compared to analysts’ expectations of $39.16 million. As a group, equities analysts forecast that GRAIL, Inc. will post -10.99 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on GRAL. Robert W. Baird set a $70.00 target price on GRAIL in a report on Wednesday, May 6th. Canaccord Genuity Group reduced their target price on GRAIL from $105.00 to $80.00 and set a “buy” rating on the stock in a report on Friday, February 20th. Morgan Stanley cut their price objective on GRAIL from $110.00 to $60.00 and set an “equal weight” rating on the stock in a report on Tuesday, February 24th. Mizuho began coverage on GRAIL in a report on Friday, April 10th. They set a “neutral” rating and a $58.00 price objective on the stock. Finally, Wall Street Zen upgraded GRAIL from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Four equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $67.00.

Hedge Funds Weigh In On GRAIL

Several institutional investors have recently modified their holdings of the business. Farallon Capital Management LLC lifted its holdings in shares of GRAIL by 73.7% during the 4th quarter. Farallon Capital Management LLC now owns 2,342,684 shares of the company’s stock valued at $200,510,000 after purchasing an additional 993,684 shares in the last quarter. Baker BROS. Advisors LP lifted its holdings in shares of GRAIL by 27.9% during the 4th quarter. Baker BROS. Advisors LP now owns 2,085,333 shares of the company’s stock valued at $178,484,000 after purchasing an additional 455,208 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of GRAIL by 9.0% during the 4th quarter. Vanguard Group Inc. now owns 1,980,783 shares of the company’s stock valued at $169,535,000 after purchasing an additional 163,790 shares in the last quarter. State Street Corp lifted its stake in GRAIL by 38.8% in the 4th quarter. State Street Corp now owns 1,827,523 shares of the company’s stock valued at $156,418,000 after acquiring an additional 510,546 shares in the last quarter. Finally, Morgan Stanley lifted its stake in GRAIL by 63.8% in the 4th quarter. Morgan Stanley now owns 1,511,687 shares of the company’s stock valued at $129,385,000 after acquiring an additional 588,647 shares in the last quarter.

GRAIL Company Profile

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.